Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

348P - Up-regulation of sorcin promotes glioblastoma progression via activating the PI3K/AKT/mTOR pathway

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Biology

Tumour Site

Presenters

Zhangya Pu

Citation

Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674

Authors

Z. Pu1, Y. Zhu2, F. Peng2

Author affiliations

  • 1 Departmetn Of Infectious Disease, Xiangya Hospital of Central South University, 410008 - Changsha/CN
  • 2 Nhc Key Laboratory Of Cancer Proteomics, Xiangya Hospital of Central South University, 410008 - Changsha/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 348P

Background

Glioblastoma (GBM) is one of the most common malignant intracranial tumors exhibiting highly aggressive and invasive features. Sorcin (SRI) is a soluble calcium (Ca2+)-binding protein, one prominent member of penta-EF-hand (PEF) protein family, and was involved in the tumorigenesis. In this study, the expression of SRI and the functional role in the progression of GBM were investigated.

Methods

The expression of SRI in GBM was examined in Oncomine and TCGA database and was further measured in clinical tissues and cell lines by immunohistochemical staining, western blot, and RT-PCR. The biological functions of SRI in GBM were performed in vitro models and the underlying molecular mechanisms were further investigated.

Results

We found that SRI expression was up-regulated in GBM tissues and cells compared to nontumorous samples. The results in vitro demonstrated that tumor proliferation is facilitated by the upregulation of SRI. Concurrently, the migration and invasion of GBM cells were significantly enhanced. Reversely, knocking down of SRI expression attenuated the pro-GBM activities. We further indicated that the overexpression of SRI promoted the epithelial-mesenchymal transformation (EMT) and significantly triggered the PI3K/AKT/mTOR pathway in GBM cells, which was hindered by depletion of SRI. Moreover, the key variant of SRI with a mutation at the number of 159 amino acid was identified and played a crucial role in promoting the oncogenic behaviors induced by SRI overexpression.

Conclusions

Collectively, these findings suggest that SRI was up-regulated in GBM and functions as an oncogenic role in the progression of GBM via triggering the PI3K/AKT/mTOR pathway. Then it highlights that SRI may represent a valuable therapeutic target for the clinical intervention of GBM.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The National Natural Sciences Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.